Jump to content

Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 Chemistry 2 References 3 External links

Technetium (^99mTc) exametazime

●日本語 ●Српски / srpski ●Srpskohrvatski / српскохрватски ●Tiếng Việt Edit links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Technetium (^99mTc) exametazime
Clinical data

Trade names	Ceretec
License data	US FDA: Ceretec
Routes of administration	Intravenous
ATC code	V09AA01 (WHO) V09HA02 (WHO) (labelled leucocytes)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name [[(3RS,3'RS)-3,3'-[(2,2-Dimethyltrimethylene)diimino][di-2-butanone]dioximato](^3–)-N,N',N'',N''']oxotechnetium (^99mTc)
CAS Number	99944-78-2^N
PubChem CID	9552069
UNII	3B744AG22N
Chemical and physical data
Formula	C₁₃H₂₅N₄O₃Tc
Molar mass	383 g·mol⁻¹
3D model (JSmol)	Interactive image Interactive image
Chirality	racemic
SMILES CC1(C)CN2[Tc]3(N4C1)([N](O[H]O[N]3=C(C)[C@H]4C)=C(C)[C@H]2C)=O CC1(C)CN2[Tc]3(N4C1)([N](O[H]O[N]3=C(C)[C@@H]4C)=C(C)[C@@H]2C)=O
^NY (what is this?) (verify)

Technetium (^99mTc) exametazime is a radiopharmaceutical sold under the trade name Ceretec, and is used by nuclear medicine physicians for the detection of altered regional cerebral perfusion in stroke^[1] and other cerebrovascular diseases. It can also be used for the labelling of leukocytes to localise intra-abdominal infections^[2] and inflammatory bowel disease.^[3] Exametazime (the part without technetium) is sometimes referred to as hexamethylpropylene amine oximeorHMPAO, although correct chemical names are:^[4]

(NE)-N-[(3R)-3-[[3-[[(2R,3E)-3-hydroxyiminobutan-2-yl]amino]-2,2-dimethylpropyl]amino]butan-2-ylidene]hydroxylamine
or 3,3'-((2,2,-dimethyl-1,3-propanediyl)diimino)bis-2-butanone dioxime.

Chemistry[edit]

One of the two enantiomers of exametazime

The drug consists of exametazime as a chelating agent for the radioisotope technetium-99m. Both enantiomeric forms of exametazime are used—the drug is racemic.^[5] The third stereoisomer of this structure, the meso form, is not included.

References[edit]

^ Moretti JL, Defer G, Cinotti L, Cesaro P, Degos JD, Vigneron N, et al. (1990). ""Luxury perfusion" with 99mTc-HMPAO and 123I-IMP SPECT imaging during the subacute phase of stroke". European Journal of Nuclear Medicine. 16 (1): 17–22. doi:10.1007/BF01566007. PMID 2307169. S2CID 11934803.

^ Weldon MJ, Joseph AE, French A, Saverymuttu SH, Maxwell JD (October 1995). "Comparison of 99m technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess". Gut. 37 (4): 557–64. doi:10.1136/gut.37.4.557. PMC 1382910. PMID 7489945.

^ Ui K, Yamaguchi T (December 1991). "[Therapy and diagnosis of emergency shock patients]". Nihon Naika Gakkai Zasshi. The Journal of the Japanese Society of Internal Medicine. 80 (12): 1892–6. doi:10.2169/naika.80.1892. PMID 1804909.

^ "Exametazime". PubChem. National Institutes of Health.

^ "Monography in the European Pharmacopoeia" (PDF).